Anti-Human MET Recombinant Antibody (Emibetuzumab) (CAT#: TAB-H24)

Figure 1 Waterfall plot for best response and treatment duration.

A, Waterfall plot of maximum percent change in sum of target lesions relative to baseline for emibetuzumab monotherapy. aThe patient had colorectal cancer. bThe patient had ovarian cancer. cThe patient had adenocarcinoma of colon. Progressive disease due to appearance of new lesions. dThe patient had transitional cell carcinoma. B, Waterfall plot of maximum percent change in sum of target lesions relative to baseline for emibetuzumab + erlotinib. aBoth patients were enrolled to this study immediately following progression on erlotinib monotherapy, having only recorded stable disease during this prior erlotinib treatment. Immunohistochemical analysis of available tumor tissue samples from both patients was positive for MET expression.

Rosen, L. S., Goldman, J. W., Algazi, A. P., Turner, P. K., Moser, B., Hu, T.,... & Banck, M. (2017). A first-in-human phase I study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer. Clinical Cancer Research, 23(8), 1910-1919.

Figure 2 MET kinase inhibitors but not emibetuzumab inhibited MET signaling pathway in Hs746t cells in vitro by western blot analysis.

Hs746t cells were treated for 24 h with 133 nM (20 μg/ml) or 667 nM (100 μg/ml) emibetuzumab or MET kinase inhibitors (merestinib, PF04217903, crizotinib, cabozantinib) at 15.6, 62.5, 250 or 1000 Nm.

Rosen, L. S., Goldman, J. W., Algazi, A. P., Turner, P. K., Moser, B., Hu, T.,... & Banck, M. (2017). A first-in-human phase I study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer. Clinical Cancer Research, 23(8), 1910-1919.